Zhang Hao, Xu Qiaoyu, Tan Chunlu, Wang Xing, Peng Bing, Liu Xubao, Li Kezhou
Department of Pancreatic Surgery.
Department of Outpatient, West China Hospital, Sichuan University, Chengdu, China.
Medicine (Baltimore). 2019 Aug;98(34):e16946. doi: 10.1097/MD.0000000000016946.
For benign and borderline tumors in the pancreatic neck and proximal body, laparoscopic spleen-preserving distal pancreatectomy (LSPDP) and laparoscopic central pancreatectomy (LCP) are alternative surgical procedures. Choosing between LSPDP and LCP is difficult. This retrospective cohort study was looking forward to provide evidence for clinical decision.A total of 59 patients undergoing LSPDP (Kimura procedure) and LCP between June 2013 and March 2017 were selected. The clinical outcomes of patients were compared by χ test or Fisher exact test and Student t test.This study included 36 patients in LSPDP group, and 23 patients in LCP group. The overall complications incidence in LCP group was significantly higher than LSPDP group (35 vs 6%, P = .004), and the postoperative pancreatic fistula (POPF) (grade B and C) rate and abdominal infection rate in LCP group were still significantly higher than LSPDP group (POPF 22 vs 3%, P = .019; abdominal infection 35 vs 3%, P = .001, respectively). The length of resected pancreas was significantly longer in LSPDP group (9.8 ± 2.0 vs 5.3 ± 1.1 cm, P = .007). The median follow-up was 39 months (range 12-57 months). No patient was confronted by tumor recurrence. The proportion of postoperative pancreatin and insulin treatment in LCP group were similar to LSPDP group (9 vs 17%, P = .383; 0 vs 3%, P = 1.000, respectively).For patients with poor general condition, the safety of LCP needs to be taken seriously; in some ways, LSPDP may be more secure, physiological, and easier operation for tumor located in pancreatic neck and proximal body.
对于胰颈和胰体近端的良性及交界性肿瘤,腹腔镜保脾远端胰腺切除术(LSPDP)和腹腔镜中央胰腺切除术(LCP)是可供选择的手术方式。在LSPDP和LCP之间做出选择很困难。这项回顾性队列研究旨在为临床决策提供依据。选取了2013年6月至2017年3月期间接受LSPDP(木村术式)和LCP的59例患者。通过χ检验或Fisher精确检验以及Student t检验比较患者的临床结局。
本研究中,LSPDP组有36例患者,LCP组有23例患者。LCP组的总体并发症发生率显著高于LSPDP组(35%对6%,P = 0.004),LCP组的术后胰瘘(B级和C级)发生率及腹腔感染率仍显著高于LSPDP组(胰瘘22%对3%,P = 0.019;腹腔感染35%对3%,P = 0.001)。LSPDP组切除胰腺的长度显著更长(9.8±2.0对5.3±1.1 cm,P = 0.007)。中位随访时间为39个月(范围12 - 57个月)。无患者出现肿瘤复发。LCP组术后胰酶和胰岛素治疗的比例与LSPDP组相似(分别为9%对17%,P = 0.383;0对3%,P = 1.000)。
对于一般状况较差的患者,LCP的安全性需要认真考虑;在某些方面,对于位于胰颈和胰体近端部位的肿瘤,LSPDP可能更安全、符合生理且操作更简便。